Improved Self-management for Patients on Ventricular Assist Device (VAD) (SELMA)

November 5, 2020 updated by: Christiane Kugler, University of Freiburg

Improved Health Care for People With Chronic Heart Disease and Implanted Cardiac Support Through Curricular Self-management - Phase 1: Prevalence Study

The number of patients with end-stage heart disease requiring the implantation of ventricular assist devices (VAD) is steadily increasing. Living with a VAD exposes the patients to multiple challenges and the need to learn complex self-management skills. Inadequate self-management can lead to serious complications (e.g. bleeding or wound infections) and impair the psychosocial outcome. This study aims to provide multi-centered actual analysis of self-management capabilities as well as analyzing moderating predictors in VAD patients through standardized prevalence assessment. Using a cross-sectional design, this prevalence study will be conducted at four established German heartcenters (Freiburg, Berlin, Bad Oeynhausen, Leipzig). VAD-patients are questioned about their self-management skills using standardized Patient-reported outcome (PRO) measures. Secondary PRO measures include health-related quality of life, symptoms of anxiety and depression, post-traumatic stress symptoms, social support, and changed body-image. Relevant complications (bleeding, wound infections, thromboembolic neurological events) are taken from the patient records. Based on a conservative sample size estimation inclusion of 450 patients is envisioned. The expected results may contribute to an improved assessment of the current situation in terms of self-management skills and needs for curricular training concepts and psychosocial concomitant therapy. Long-term, the study results contribute to improve the health care for long-term VAD patients.

Study Overview

Detailed Description

The number of patients with end-stage heart disease requiring the implantation of ventricular assist devices (VAD) is steadily increasing. Due to advanced compensatory technological developments, VAD support has been established as a recognized therapy concept for the long-term care of those affected. Indications include a multi-year bridging therapy (up to 10 years) and increasingly a destination therapy. The Euromacs Register published the second report in 2018 and reported 2,947 registered VAD implantations in 2016 (+257 percent). Euromacs further points to a rising trend and demand for the use of VAD systems. In Germany, an increase of VAD implantation by 36.6 percent has been reported since 2011. The position paper of the German Society of Cardiology (2016) points to the fact that the range of indications for VAD implantation for patients with chronic heart disease will continue to change. The ISHLT Guideline (International Society for Heart and Lung Transplantation), published in 2018, calls for psychosocial care and standardized self-management skills for patients before, during, and in the long-term after VAD implantation. This is currently being implemented inconsistently in terms of structure and quality in German cardiac centers. After VAD implantation, patients and their relatives must be able to follow a complex therapeutic regimen. They need comprehensive knowledge as well as self-management skills for the safe management of everyday life in a domestic setting. These self-management capabilities include the so-called device handling (for example dealing with the technical equipment including battery replacement and controller monitoring), to perform the wound care of the driveline, to carry out anticoagulation measurements and adapted revenues of oral anticoagulant, to take further medication, to monitor vital signs (for example blood pressure, temperature) and, in the case of symptoms, to take adequate measures to prevent further complications (for example prompt information from the heart center on the onset of symptoms). In addition, lifestyle changes are an essential part of the success of long-term therapy. This requires a sufficient degree of self-management ability and mental stability. In addition, it is important to emotionally accept the dependence of a device on the heart, the changed body image, to cope with fears of (real potential) malfunctions and complications and to build up a subjective quality of life with a constant, visible and tangible companion at heart. The mental health of all those affected is considered to be in need of observation, although there is currently no reliable prevalence data on mental disorders. In a first survey in 2006, 64% had at least one psychologically / psychiatric treatment requiring diagnosis. All this shows, the challenges VAD patients have to face are complex. Thus, this study aims to provide multi-centered actual analysis of self-management capabilities as well as analyzing moderating predictors in VAD patients through standardized PRO prevalence assessment. The prevalence survey should be conducted in all outpatients (at least 3 months up to a maximum of 3 years at the VAD) in four established German cardiac centers (Freiburg, Berlin, Bad Oeynhausen, Leipzig). The study focuses on those involved in outpatient care, as they had to integrate the VAD into their daily lives after implantation and are able to report deficits, resources and needs on the basis of their experience of self-management. As an assessment instrument a standardized PRO measure was chosen to identify self-management skills and needs. Secondary PRO measures include health-related quality of life, symptoms of anxiety, depression and post-traumatic stress, as well as social support. Relevant complications (bleeding, wound infections, thromboembolic neurological events) are taken from the patient records. Based on a conservative sample size estimation inclusion of 450 patients is envisioned. The expected results may contribute to an improved assessment of the current situation in terms of self-management skills and needs for curricular training concepts and psychosocial concomitant therapy. Long-term, the study results contribute to improve the health care for long-term VAD patients. The study is planned to continue in a second and third phase to develop and test a standardized self-management care for VAD patients in Germany.

Study Type

Observational

Enrollment (Actual)

393

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Berlin, Germany, 13353
        • German Heart Center
    • Baden-Württemberg
      • Freiburg, Baden-Württemberg, Germany, 79110
        • University Heart Center Freiburg
    • North Rhine-Westphalia
      • Bad Oeynhausen, North Rhine-Westphalia, Germany, 32545
        • Heart and Diabetes Center North Rhine-Westphalia
    • Sachsen
      • Leipzig, Sachsen, Germany, 04289
        • Leipzig Heart Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients implanted with a ventricular assist device in the outpatient setting of four heart centers in Germany (Freiburg, Berlin, Bad Oeynhausen and Leipzig).

Description

Inclusion Criteria:

  • Outpatient at the respective heart center
  • Living in a home environment
  • On device between 3 months and 3 years
  • 18 years and older
  • No contraindications (e.g. cognitive, language)
  • Signed Informed Consent

Exclusion Criteria:

  • In-patient stay
  • Not living in a home environment (e.g. assisted living)
  • On device less than 3 months or more than 3 years
  • Underage
  • Contraindications (e.g. cognitive, language)
  • No signed Informed Consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
VAD Patients
Patients with implanted ventricular assist device in the outpatient setting
Questionnaire survey on self-management

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Self-management Skills
Time Frame: October 2019 till January 2020
As an assessment instrument a standardized PRO measure was chosen to identify self-management skills and needs.
October 2019 till January 2020

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Health-related Quality of Life
Time Frame: October 2019 till January 2020
The experienced health-related quality of life of the participants measured with a selfassessment questionnaire (QoL-VAD, KCCQ).
October 2019 till January 2020
Social Support
Time Frame: October 2019 till January 2020
The experienced social support of the participants measured with a selfassessment questionnaire (F-SozU).
October 2019 till January 2020
Symptoms of Anxiety
Time Frame: October 2019 till January 2020
Symptoms of anxiety measured via screening tool (HADS).
October 2019 till January 2020
Symptoms of Depression
Time Frame: October 2019 till January 2020
Symptoms of depression measured via screening tool (HADS, PHQ-9).
October 2019 till January 2020
Symptoms of Posttraumatic Stress Disorder
Time Frame: October 2019 till January 2020
Symptoms of posttraumatic stress disorder measured via screening tool (PTSD-7).
October 2019 till January 2020

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comorbidities
Time Frame: October 2019 till January 2020
Relevant comorbidities (e.g. Diabetes, Hypertension, psychic comorbidities) will be taken from the medical record of the participants.
October 2019 till January 2020
VAD Type
Time Frame: October 2019 till January 2020
Information on implanted VAD type (HVAD, HMIII or other) will be taken from the medical record of the participants.
October 2019 till January 2020
New York Heart Association (NYHA) classification
Time Frame: October 2019 till January 2020
Information on New York Heart Association (NYHA) classification of the participants will be taken from their medical record.
October 2019 till January 2020
VAD-related complications
Time Frame: October 2019 till January 2020
Emerged VAD-related complications (e.g. neurologic events, major bleeding events, infections) will be taken from the patients' medical record.
October 2019 till January 2020

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Christiane Kugler, Prof. Dr., University of Freiburg
  • Principal Investigator: Christiane Kugler, Prof. Dr., University of Freiburg

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2019

Primary Completion (Actual)

August 31, 2020

Study Completion (Actual)

September 30, 2020

Study Registration Dates

First Submitted

October 2, 2019

First Submitted That Met QC Criteria

January 17, 2020

First Posted (Actual)

January 21, 2020

Study Record Updates

Last Update Posted (Actual)

November 6, 2020

Last Update Submitted That Met QC Criteria

November 5, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 01VSF18012

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Self-management

Clinical Trials on Prevalence Survey

3
Subscribe